Catalyst Pharmaceutical CPRX Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Catalyst Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Catalyst Pharmaceutical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Catalyst Pharmaceutical's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Catalyst Pharmaceutical's accrued expenses?
- Catalyst Pharmaceutical (CPRX) reported accrued expenses of $125.25M in Q1 2026.
- How has Catalyst Pharmaceutical's accrued expenses changed year-over-year?
- Catalyst Pharmaceutical's accrued expenses increased by 24.7% year-over-year, from $100.45M to $125.25M.
- What is the long-term trend for Catalyst Pharmaceutical's accrued expenses?
- Over 5 years (2020 to 2025), Catalyst Pharmaceutical's accrued expenses has grown at a 49.0% compound annual growth rate (CAGR), from $18.5M to $135.95M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.